Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely amlodipine (as amlodipine besilate) 10 milligram and hydrochlorothiazide 25 milligram and valsartan 320 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely amlodipine (as amlodipine besilate) 10 milligram and hydrochlorothiazide 25 milligram and valsartan 320 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aspirin 325 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aspirin 325 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Sulfabenzamide 184 mg and sulfacetamide sodium 144 mg and sulfathiazole 172 mg vaginal tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely magnesium hydroxide 700 milligram and omeprazole 40 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely magnesium hydroxide 700 milligram and omeprazole 40 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Product containing precisely magnesium hydroxide 700 milligram and omeprazole 40 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely magnesium hydroxide 700 milligram and omeprazole 40 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely estradiol 25 microgram/1 each conventional release vaginal tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely estradiol 25 microgram/1 each conventional release vaginal tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Nicotinic acid 750 mg and simvastatin 20 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Nicotinic acid 750 mg and simvastatin 20 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Nicotinic acid 750 mg and simvastatin 20 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Trazodone hydrochloride 150 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Trazodone hydrochloride 150 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely risperidone 3 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely risperidone 3 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely erythromycin 333 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely erythromycin 333 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
pramipexoldihydroklorid 3 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
pramipexoldihydroklorid 3 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Diphenhydramine hydrochloride 12.5 mg chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Diphenhydramine hydrochloride 12.5 mg chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Mirtazapine 15 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Mirtazapine 15 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg and valsartan 160 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg and valsartan 160 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg and valsartan 160 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg and valsartan 160 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Cetirizine hydrochloride 5 mg chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Cetirizine hydrochloride 5 mg chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely trimethadione 150 milligram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely trimethadione 150 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Olanzapine 5 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Olanzapine 5 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely aspirin 75 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aspirin 75 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Potassium chloride 1.5 g prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Potassium chloride 1.5 g prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely nicotinic acid 500 milligram and simvastatin 20 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely nicotinic acid 500 milligram and simvastatin 20 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely nicotinic acid 500 milligram and simvastatin 20 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Desloratadine 2.5 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Desloratadine 2.5 mg orodispersible tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 5 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 5 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 5 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 5 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely mirtazapine 30 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely mirtazapine 30 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Aliskiren (as aliskiren fumarate) 300 mg and amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Aliskiren (as aliskiren fumarate) 300 mg and amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aliskiren (as aliskiren fumarate) 300 mg and amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Aliskiren (as aliskiren fumarate) 300 mg and amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 25 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Product containing precisely sodium salicylate 650 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely sodium salicylate 650 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Cetirizine hydrochloride 10 mg chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Cetirizine hydrochloride 10 mg chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Fentanyl 400 microgram buccal tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Fentanyl 400 microgram buccal tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Doxycycline (as doxycycline hyclate) 150 mg gastro-resistant oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Doxycycline (as doxycycline hyclate) 150 mg gastro-resistant oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely famotidine 10 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely famotidine 10 milligram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bupropion hydrobromide 522 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bupropion hydrobromide 522 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 10 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 10 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 10 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely aliskiren (as aliskiren fumarate) 300 milligram and amlodipine (as amlodipine besilate) 10 milligram and hydrochlorothiazide 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely olanzapine 10 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely olanzapine 10 milligram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Nicotinic acid 250 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Nicotinic acid 250 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely fentanyl 200 microgram/1 each conventional release buccal tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely fentanyl 200 microgram/1 each conventional release buccal tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Erythromycin ethyl succinate 200 mg chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Erythromycin ethyl succinate 200 mg chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely axitinib 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely axitinib 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
pramipexoldihydroklorid 1,5 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
pramipexoldihydroklorid 1,5 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely risedronate sodium 35 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely risedronate sodium 35 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
pramipexoldihydroklorid 4,5 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
pramipexoldihydroklorid 4,5 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Fentanyl 300 microgram buccal tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Fentanyl 300 microgram buccal tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely risperidone 500 microgram/1 each conventional release orodispersible tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely risperidone 500 microgram/1 each conventional release orodispersible tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Risperidone 4 mg orodispersible tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |